Wakamoto Pharmaceutical Co.,Ltd. (4512.T)
JPY 332.0
(-0.9%)
JPY 332.0
(-0.9%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 3.39 Billion JPY | -10.77% |
| 2022 | 3.8 Billion JPY | 9.57% |
| 2021 | 3.47 Billion JPY | 8.97% |
| 2020 | 3.18 Billion JPY | -21.04% |
| 2019 | 4.03 Billion JPY | 0.83% |
| 2018 | 4 Billion JPY | 4.04% |
| 2017 | 3.84 Billion JPY | -3.61% |
| 2016 | 3.99 Billion JPY | -7.78% |
| 2015 | 4.32 Billion JPY | -10.69% |
| 2014 | 4.84 Billion JPY | -20.31% |
| 2013 | 6.08 Billion JPY | 23.78% |
| 2012 | 4.91 Billion JPY | 3.5% |
| 2011 | 4.74 Billion JPY | -5.29% |
| 2010 | 5.01 Billion JPY | -0.38% |
| 2009 | 5.03 Billion JPY | 0.99% |
| 2008 | 4.98 Billion JPY | 17.3% |
| 2007 | 4.24 Billion JPY | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 3.43 Billion JPY | 1.31% |
| 2023 Q3 | 3.55 Billion JPY | -5.97% |
| 2023 Q4 | 3.39 Billion JPY | -4.46% |
| 2023 Q1 | 3.5 Billion JPY | -7.9% |
| 2023 FY | 3.39 Billion JPY | -10.77% |
| 2023 Q2 | 3.77 Billion JPY | 7.84% |
| 2022 Q1 | 3.27 Billion JPY | -5.82% |
| 2022 FY | 3.8 Billion JPY | 9.57% |
| 2022 Q4 | 3.8 Billion JPY | 12.71% |
| 2022 Q3 | 3.37 Billion JPY | 6.88% |
| 2022 Q2 | 3.15 Billion JPY | -3.42% |
| 2021 Q2 | 3.39 Billion JPY | 5.76% |
| 2021 Q4 | 3.47 Billion JPY | 4.27% |
| 2021 Q3 | 3.33 Billion JPY | -1.97% |
| 2021 FY | 3.47 Billion JPY | 8.97% |
| 2021 Q1 | 3.21 Billion JPY | 0.8% |
| 2020 Q4 | 3.18 Billion JPY | -1.42% |
| 2020 Q1 | 3.88 Billion JPY | -3.64% |
| 2020 Q2 | 3.62 Billion JPY | -6.81% |
| 2020 Q3 | 3.23 Billion JPY | -10.81% |
| 2020 FY | 3.18 Billion JPY | -21.04% |
| 2019 Q4 | 4.03 Billion JPY | -7.29% |
| 2019 FY | 4.03 Billion JPY | 0.83% |
| 2019 Q3 | 4.35 Billion JPY | 6.66% |
| 2019 Q2 | 4.08 Billion JPY | 8.11% |
| 2019 Q1 | 3.77 Billion JPY | -5.68% |
| 2018 Q3 | 3.64 Billion JPY | -4.94% |
| 2018 FY | 4 Billion JPY | 4.04% |
| 2018 Q4 | 4 Billion JPY | 9.85% |
| 2018 Q2 | 3.83 Billion JPY | 0.97% |
| 2018 Q1 | 3.79 Billion JPY | -1.32% |
| 2017 Q4 | 3.84 Billion JPY | -6.67% |
| 2017 FY | 3.84 Billion JPY | -3.61% |
| 2017 Q3 | 4.12 Billion JPY | 2.62% |
| 2017 Q2 | 4.01 Billion JPY | -2.36% |
| 2017 Q1 | 4.11 Billion JPY | 3.07% |
| 2016 Q1 | 4.31 Billion JPY | -0.27% |
| 2016 FY | 3.99 Billion JPY | -7.78% |
| 2016 Q4 | 3.99 Billion JPY | 3.79% |
| 2016 Q3 | 3.84 Billion JPY | -3.84% |
| 2016 Q2 | 3.99 Billion JPY | -7.35% |
| 2015 Q2 | 4.64 Billion JPY | -2.04% |
| 2015 FY | 4.32 Billion JPY | -10.69% |
| 2015 Q4 | 4.32 Billion JPY | -10.05% |
| 2015 Q1 | 4.74 Billion JPY | -2.07% |
| 2015 Q3 | 4.81 Billion JPY | 3.5% |
| 2014 FY | 4.84 Billion JPY | -20.31% |
| 2014 Q2 | 4.97 Billion JPY | -5.23% |
| 2014 Q4 | 4.84 Billion JPY | -2.42% |
| 2014 Q3 | 4.96 Billion JPY | -0.24% |
| 2014 Q1 | 5.25 Billion JPY | -13.62% |
| 2013 Q2 | 4.48 Billion JPY | -11.62% |
| 2013 Q3 | 4.53 Billion JPY | 1.16% |
| 2013 Q4 | 6.08 Billion JPY | 34.19% |
| 2013 FY | 6.08 Billion JPY | 23.78% |
| 2013 Q1 | 5.06 Billion JPY | 3.17% |
| 2012 Q3 | 4.65 Billion JPY | -2.44% |
| 2012 Q4 | 4.91 Billion JPY | 5.59% |
| 2012 Q2 | 4.76 Billion JPY | 0.14% |
| 2012 FY | 4.91 Billion JPY | 3.5% |
| 2012 Q1 | 4.76 Billion JPY | 0.34% |
| 2011 Q2 | 5.12 Billion JPY | -0.27% |
| 2011 FY | 4.74 Billion JPY | -5.29% |
| 2011 Q3 | 4.88 Billion JPY | -4.56% |
| 2011 Q1 | 5.13 Billion JPY | 2.49% |
| 2011 Q4 | 4.74 Billion JPY | -2.92% |
| 2010 Q4 | 5.01 Billion JPY | -2.13% |
| 2010 FY | 5.01 Billion JPY | -0.38% |
| 2010 Q1 | 5.26 Billion JPY | 4.62% |
| 2010 Q2 | 5.16 Billion JPY | -1.83% |
| 2010 Q3 | 5.12 Billion JPY | -0.9% |
| 2009 Q4 | 5.03 Billion JPY | -1.94% |
| 2009 Q3 | 5.13 Billion JPY | -17.48% |
| 2009 Q2 | 6.21 Billion JPY | 0.0% |
| 2009 FY | 5.03 Billion JPY | 0.99% |
| 2008 Q3 | 5.02 Billion JPY | 0.0% |
| 2008 Q4 | 4.98 Billion JPY | -0.94% |
| 2008 FY | 4.98 Billion JPY | 17.3% |
| 2007 FY | 4.24 Billion JPY | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Pharma Foods International Co., Ltd. | 24.98 Billion JPY | 86.414% |
| Takeda Pharmaceutical Company Limited | 7834.78 Billion JPY | 99.957% |
| Sumitomo Pharma Co., Ltd. | 751.37 Billion JPY | 99.548% |
| Shionogi & Co., Ltd. | 164.35 Billion JPY | 97.934% |
| Nippon Shinyaku Co., Ltd. | 42.86 Billion JPY | 92.08% |
| Kaken Pharmaceutical Co., Ltd. | 27.86 Billion JPY | 87.817% |
| Eisai Co., Ltd. | 494.82 Billion JPY | 99.314% |
| Morishita Jintan Co., Ltd. | 5.04 Billion JPY | 32.639% |
| Hisamitsu Pharmaceutical Co., Inc. | 61.69 Billion JPY | 94.497% |
| Mochida Pharmaceutical Co., Ltd. | 30.83 Billion JPY | 88.989% |
| Fuso Pharmaceutical Industries,Ltd. | 39.79 Billion JPY | 91.469% |
| Nippon Chemiphar Co., Ltd. | 31.08 Billion JPY | 89.078% |
| Tsumura & Co. | 132.88 Billion JPY | 97.445% |
| Kissei Pharmaceutical Co., Ltd. | 39.79 Billion JPY | 91.468% |
| Torii Pharmaceutical Co., Ltd. | 13.29 Billion JPY | 74.468% |
| Towa Pharmaceutical Co., Ltd. | 274.75 Billion JPY | 98.764% |
| Fuji Pharma Co., Ltd. | 44.15 Billion JPY | 92.312% |
| Zeria Pharmaceutical Co., Ltd. | 70.7 Billion JPY | 95.198% |
| KYORIN Holdings, Inc. | 46.89 Billion JPY | 92.76% |
| Taiko Pharmaceutical Co.,Ltd. | 7 Billion JPY | 51.521% |
| Daito Pharmaceutical Co.,Ltd. | 25.43 Billion JPY | 86.654% |
| SymBio Pharmaceuticals Limited | 8.14 Billion JPY | 58.304% |
| MedRx Co., Ltd | 129 Million JPY | -2531.767% |
| Mizuho Medy Co.,Ltd. | 3.27 Billion JPY | -3.742% |
| Solasia Pharma K.K. | 673 Million JPY | -404.455% |
| Modalis Therapeutics Corporation | 645.5 Million JPY | -425.943% |
| ASKA Pharmaceutical Holdings Co.,Ltd. | 31.38 Billion JPY | 89.181% |
| Sawai Group Holdings Co., Ltd. | 163.99 Billion JPY | 97.93% |
| Cyfuse Biomedical K.K. | 1.01 Billion JPY | -235.691% |
| Toho Holdings Co., Ltd. | 523.98 Billion JPY | 99.352% |
| Koa Shoji Holdings Co.,Ltd. | 6.95 Billion JPY | 51.168% |